Theriva Biologics, Inc.
TOVX
$0.25
$0.014.52%
AMEX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 21.45% | 35.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.48% | -25.45% | |||
| Operating Income | 25.05% | 25.45% | |||
| Income Before Tax | -2.40% | 54.23% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2.40% | 54.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.40% | 54.23% | |||
| EBIT | 25.05% | 25.45% | |||
| EBITDA | 25.19% | 25.62% | |||
| EPS Basic | 58.43% | 73.42% | |||
| Normalized Basic EPS | 47.47% | 75.42% | |||
| EPS Diluted | 58.43% | 73.42% | |||
| Normalized Diluted EPS | 47.47% | 75.42% | |||
| Average Basic Shares Outstanding | 40.30% | 202.54% | |||
| Average Diluted Shares Outstanding | 40.30% | 202.54% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||